94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Immunol.
Sec. Alloimmunity and Transplantation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1595951
Corrigendum: QUALITY OF LIFE IMPROVEMENTS AND CLINICAL ASSESSMENTS IN KIDNEY TRANSPLANT RECIPIENTS UNDERGOING PEGLOTICASE TREATMENT FOR UNCONTROLLED GOUT: FINDINGS OF THE PHASE 4 PROTECT CLINICAL TRIAL
Provisionally accepted- 1Amgen (United States), Thousand Oaks, United States
- 2Baylor College of Medicine, Houston, Texas, United States
- 3School of Medicine, Stanford University, Stanford, California, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Corrigendum on: Abdellatif A, Zhao L, Obermeyer K, Vranic Z, Marder BA and Scandling JD (2025) Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trial. Front. Immunol. 16:1516146. doi: 10.3389/fimmu.2025.1516146In the published article, the reference for [The high impact of gout on lowering patient QOL is well established, and these effects are more pronounced in KT recipients] was incorrectly written as [40]. It should be [27].The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: Gout, Kidney transplant, urate, Quality of Life, Renal function, Blood Pressure
Received: 18 Mar 2025; Accepted: 25 Mar 2025.
Copyright: © 2025 Marder, Abdellatif, Zhao, Obermeyer, Vranic and Scandling. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Brad Marder, Amgen (United States), Thousand Oaks, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.